Scarica l'app Stockscreener
2.52
4.94%
-0.131
Precedente Chiudi:
$2.651
Aprire:
$2.6
Volume 24 ore:
1,244
Relative Volume:
0.04
Capitalizzazione di mercato:
$3.52M
Reddito:
-
Utile/perdita netta:
$-560.20K
Rapporto P/E:
-1.7379
EPS:
-1.45
Flusso di cassa netto:
$-6.90M
1 W Prestazione:
-3.45%
1M Prestazione:
-30.00%
6M Prestazione:
-49.09%
1 anno Prestazione:
-62.11%
Intervallo 1D:
$2.60
$2.60
Intervallo di 1 settimana:
$2.32
$2.75
Portata 52W:
$2.32
$8.775
Synaptogenix Inc Stock (SNPX) Company Profile
Nome
Synaptogenix Inc
Settore
Industria
Telefono
(973) 242-0005
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Confronta SNPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SNPX | 2.60 | 3.52M | 0 | -560.20K | -6.90M | -1.45 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.40 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.04 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.32 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Synaptogenix Inc Borsa (SNPX) Ultime notizie
Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK
Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com
Synaptogenix announces new preferred stock series - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com India
Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World
Synaptogenix extends preferred shares maturity date - Investing.com
Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix - The Pharma Letter
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
New collab to probe potential of fatty acid analogs in Alzheimer's - The Pharma Letter
Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix begins pre-clinical trials for SCI treatment - Investing.com
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - Lelezard
Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to “Buy” - Defense World
Synaptogenix (NASDAQ:SNPX) Trading Down 0.5% - Defense World
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
Synaptogenix Acquires 25% Stake In Cannasoul - Quantisnow
FDA grants IND authorisation for Synaptogenix's multiple sclerosis trial - Yahoo Finance
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Dana Incorporated names Lisa Amend as new HR Chief By Investing.com - Investing.com South Africa
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - StockTitan
Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024TipRanks.com - TipRanks
Alzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix (NASDAQ:SNPX) Stock Price Up 1% - Defense World
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report
What's Going On With Synaptogenix (SNPX) Stock?Synaptogenix (NASDAQ:SNPX) - Benzinga
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com UK
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million. - Marketscreener.com
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today
Synaptogenix Inc Azioni (SNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):